Market Overview

GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors

Share:
GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors
Related NUVA
82 Biggest Movers From Yesterday
66 Stocks Moving In Wednesday's Mid-Day Session

Short seller GlassHouse Research has accused medical device company NuVasive, Inc. (NASDAQ: NUVA) of “irregular accounting” practices and says the stock has more than 50 percent downside.

In a new report, GlassHouse claims NuVasive has been using every accounting trick in the book to mask the fact that its organic business is in decline.

GlassHouse accuses NuVasive of inflating its earnings and growth numbers using nefarious strategies such as channel stuffing, pulling forward revenue, and delaying normalized expenses.

GlassHouse says NuVasive is closely following the growth blueprint that led to Valeant Pharmaceuticals Intl Inc (NYSE: VRX)’s explosive growth and rapid downfall.

“NUVA has borrowed from the Valeant playbook and has employed an ‘acquire at all cost’ model that has helped them to artificially inflate true earnings,” GlassHouse wrote.

The company says NuVasive have been flying under the radar on Wall Street because its non-GAAP numbers seem just fine. However, the difference between NuVasive’s non-GAAP trailing 12-month EPS of $1.77 and its GAAP EPS of 62 cents has now expanded to 185.5 percent.

Finally, GlassHouse points to the recent abrupt departure of former CFO Quentin Blackford and former COO Jason Hannon within the last three months as evidence company insiders see the writing on the wall. GlassHouse says the departures suggest the clock is running out for NuVasive.

“[In] light of our concerns regarding the abrupt departure of key executives, corporate culture, lackluster free-cash-flow generation, channel-stuffing concerns, bloated AR on the balance sheet and depleted accrued expense balance, GHR finds the current stock price to be highly egregious,” the firm wrote.

GlassHouse has set a $24.18 price target for NuVasive and is predicting a major earnings miss sometime in the next three quarters.

At time of writing, the stock was trading around $56.60.

Related Link: Want To Short Bitcoin? Here Are A Few Ways

Posted-In: Citron ResearchShort Sellers Short Ideas Health Care Price Target Top Stories Trading Ideas General Best of Benzinga

 

Related Articles (NUVA + VRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

DowDuPont's Guidance Looks Conservative And Could Be Raised Soon

Ubiquiti Shares Down 0.4% 1 Day After New Citron Short Report; Co. Announced In 8-K This Morning Addition Of $100M To Buyback Plan, Guidance